Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice

被引:24
作者
Kaur, Manpreet [1 ]
Saxena, Ankur [2 ]
Rai, Anant [2 ]
Bhatnagar, Rakesh [1 ]
机构
[1] Jawaharlal Nehru Univ, Lab Mol Biol & Genet Engn, Sch Biotechnol, New Delhi 110067, Delhi, India
[2] Indian Vet Res Inst, Natl Biotechnol Ctr, Izatnagar 243122, Uttar Pradesh, India
关键词
encephalitis; intramuscular administration; rabies virus neutralizing antibodies; survival; prophylactic; therapeutic; MHC CLASS-I; CYTOTOXIC T-LYMPHOCYTES; B SURFACE-ANTIGEN; GENE-GUN; VIRUS; IMMUNOGENICITY; IMMUNIZATION; INJECTION; RESPONSES; IMMUNITY;
D O I
10.1096/fj.09-138644
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The worldwide incidence of rabies and the inability of currently used vaccination strategies to provide highly potent and cost-effective therapy indicate the need for an improved rabies vaccine. Thus, DNA vaccine based on lysosome-targeted glycoprotein of the rabies virus was evaluated in BALB/c mice. It imparted partial protection (60%) against challenge with 20 LD50 of the challenge virus standard (CVS) strain of rabies virus. To improve the outcome of vaccination, to ultimately enhance the immune response, we investigated different routes for DNA vaccine delivery, varied doses of DNA, and the influence of adjuvant supplementation. The highest immune response pertaining to IgG antibody titer, with a predominantly IgG1/IgG2a subclass distribution, effective cellular immunity, and a high level of rabies virus neutralizing antibodies (RVNAs) was attained by the optimized DNA vaccine formulation comprising intramuscular administration of 100 mu g of DNA vaccine supplemented with Emulsigen (R)-D. In preexposure prophylaxis, a 3-dose regimen of this formulation generated a high RVNA titer (32 IU/ml) and conferred complete protection against challenge with 20 LD50 of CVS. For postexposure efficacy analysis, rabies was experimentally induced with 50 LD50 of CVS. Subsequent therapy with 5 doses of the formulation completely prevented rabies in BALB/c mice, which maintained protective RVNA titers of 4 IU/ml. The World Health Organization recommended rabies protective titer threshold is 0.5 IU/ml. Thus, this optimized DNA vaccine formulation provides an avenue for preventing and controlling rabies.-Kaur, M., Saxena, A., Rai, A., and Bhatnagar, R. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. FASEB J. 24, 173-183 ( 2010). www.fasebj.org
引用
收藏
页码:173 / 183
页数:11
相关论文
共 48 条
[1]   Epitope specificity of antibodies raised against enterotoxigenic Escherichia coli CFA/I fimbriae in mice immunized with naked DNA [J].
Alves, AMB ;
Lasaro, MO ;
Almeida, DF ;
Ferreira, LCS .
VACCINE, 1998, 16 (01) :9-15
[2]  
[Anonymous], 2007, Wkly Epidemiol Rec, V82, P425
[3]   Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions [J].
Bahloul, C ;
Taieb, D ;
Diouani, MF ;
Ahmed, SBH ;
Chtourou, Y ;
B'chir, BI ;
Kharmachi, H ;
Dellagi, K .
VACCINE, 2006, 24 (08) :1063-1072
[4]   Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine [J].
Bahloul, C ;
Ahmed, SBH ;
B'chir, BI ;
Kharmachi, H ;
Hayouni, EA ;
Dellagi, K .
VACCINE, 2003, 22 (02) :177-184
[5]   Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine [J].
Beran, J ;
Honegr, K ;
Banzhoff, A ;
Malerczyk, C .
VACCINE, 2005, 23 (30) :3902-3907
[6]   Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2 [J].
Chow, YH ;
Huang, WL ;
Chi, WK ;
Chu, YD ;
Tao, MH .
JOURNAL OF VIROLOGY, 1997, 71 (01) :169-178
[7]  
CONN A, 2726 BIOR LAB
[8]  
Conry RM, 2002, CLIN CANCER RES, V8, P2782
[9]  
Corr M, 1999, J IMMUNOL, V163, P4721
[10]   Gene transfer to subdermal tissues via a new gene gun design [J].
Dileo, J ;
Miller, TE ;
Chesnoy, S ;
Huang, L .
HUMAN GENE THERAPY, 2003, 14 (01) :79-87